Chargement en cours...
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1/2 inhibitor therapy is effective in decreasing the burden of sym...
Enregistré dans:
| Publié dans: | Blood |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5800543/ https://ncbi.nlm.nih.gov/pubmed/22700718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-399048 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|